Subject Predicate Object
xLSQrNcs
a
Resource
Answer
Written answer
answer has question
7UMw7TaK
answer has answering person
Jacqueline Doyle-Price
answer text
<p>The Government is committed to the safe and effective regulation of medicines in the United Kingdom; ensuring patients and the public have fast access to new, innovative medicines, including medicines for rare diseases.</p><p> </p><p>The Medicines and Healthcare products Regulatory Agency (MHRA) launched in October 2018 a consultation on the regulation of medicines in the event of a ‘no deal’ exit, which included the proposed UK approach to the regulation of orphan medicines post-exit, including on incentives to encourage such medicines onto the UK market. Following this consultation, the MHRA, on 3 January 2019, published guidance on the UK proposed arrangements for the regulation of orphan medicines, in the event of a ‘no deal’ exit. This can be accessed at the following link:</p><p> </p><p><a href="https://www.gov.uk/government/publications/further-guidance-note-on-the-regulation-of-medicines-medical-devices-and-clinical-trials-if-theres-no-brexit-deal" target="_blank">https://www.gov.uk/government/publications/further-guidance-note-on-the-regulation-of-medicines-medical-devices-and-clinical-trials-if-theres-no-brexit-deal</a></p>
answer given date
answer has answering body
Department of Health and Social Care
written answer has answering body
Department of Health and Social Care
Department of Health and Social Care
answering body has written answer
xLSQrNcs
answering body has answer
xLSQrNcs
7UMw7TaK
question has answer
xLSQrNcs
Jacqueline Doyle-Price
answering person has answer
xLSQrNcs